SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody

Catalogue No.:abx376490



SDS-PAGE analysis of recombinant SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody expressed in CHO cells against SARS-CoV-2/COVID-19 Spike Protein RBD (Omicron B.1.1.529 Variant).

The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.

The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations which appear to increase the risk of reinfection compared to other variants of concern.

Target:	SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant)
Research Area:	Infection Immunity
Clonality:	Monoclonal
Reactivity:	Virus
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	ELISA: 1/5000 - 1/10000, WB: 1/1000 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com

Immunogen:	SARS-CoV-2
Isotype:	IgG_1 Kappa
Form:	Liquid
Purification:	Purified by affinity chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	PBS, pH 7.4.
Specificity:	Detects SARS-CoV-2 Surface Glycoprotein.
Concentration:	3.64 mg/ml
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com